Drug-resistant tuberculosis among patients in Ji’nan from 2016 to 2020

doi:10.19983/j.issn.2096-8493.20210138

Abstract

Abstract:

Objective: To analyze the drug resistance situation of pulmonary tuberculosis patients in Ji’nan, in order to provide basis for the prevention and control of drug-resistant pulmonary tuberculosis. Methods: The drug resistance results of 1104 patients with sputum culture positive pulmonary tuberculosis in Ji’nan from 2016 to 2020 were analyzed by retrospective research method. The factors affecting drug resistance of pulmonary tuberculosis patients were analyzed by univariate and multivariate logistic regression model. Results: From 2016 to 2020, the total drug resistance rate of pulmonary tuberculosis patients in Ji’nan was 24.82% (274/1104), of which the drug resistance rate of newly treated patients was 21.47% (204/950), and the drug resistance rate of retreated patients was 45.45% (70/154); The single drug resistance rate was 10.14% (112/1104), the multidrug-resistance rate was 7.70% (85/1104), the pre-extensively drug-resistant tuberculosis rate was 1.54% (17/1104), and the other drug resistance rate was 5.43% (60/1104). From 2016 to 2020, the total drug resistance rate of tuberculosis patients (the drug resistance rate was 50.00% (46/92) in 2016, and 50.00% (32/64) in 2017, 24.44% (33/135) in 2018, 16.16% (58/359) in 2019, and 23.13% (105/454) in 2020) showed a downward trend, and the difference was statistically significant (χ_trend²=38.100, P<0.001). Multivariate logistic regression analysis showed that the drug resistance rate of pulmonary tuberculosis patients aged 21-40 was higher (OR=4.394, 95%CI: 1.325-14.570); The drug resistance rate of retreated pulmonary tuberculosis patients was higher (OR=3.276, 95%CI: 2.264-4.740). Conclusion: The epidemic situation of drug-resistant pulmonary tuberculosis in Ji’nan is serious. We should focus on patients aged 21-40 and retreated pulmonary tuberculosis patients.

Key words: Tuberculosis, Drug resistance, Factor analysi,statistical, Small-area analysis

CLC Number:

R521

CAI Jun-li, JING Rui, ZHANG Wen-qian, WU Hong-yan, LIU Xiao-hua. Drug-resistant tuberculosis among patients in Ji’nan from 2016 to 2020[J]. Journal of Tuberculosis and Lung Disease , 2022, 3(1): 27-32. doi: 10.19983/j.issn.2096-8493.20210138

Figures/Tables 6

References 23

[1]	Molie T, Teklemariam Z, Klinkenberg E, et al. Intensive phase treatment outcome and associated factors among patients treated for multi drug resistant tuberculosis in Ethiopia: a retrospective cohort study. BMC Infect Dis, 2019, 19(1):818. doi: 10.1186/s12879-019-4411-7. doi: 10.1186/s12879-019-4411-7 URL
[2]	Conradie F, Diacon AH, Ngubane N, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med, 2020, 382(10):893-902. doi: 10.1056/NEJMoa1901814. doi: 10.1056/NEJMoa1901814 URL
[3]	MacPherson DW, Gushulak BD. Balancing prevention and screening among international migrants with tuberculosis: population mobility as the major epidemiological influence in low-incidence nations. Public Health, 2006, 120(8):712-723. doi: 10.1016/j.puhe.2006.05.002. doi: 10.1016/j.puhe.2006.05.002 pmid: 16828821
[4]	王美花, 张文茜, 景睿, 等. 2010—2019年济南市肺结核流行特征分析. 结核与肺部疾病杂志, 2020, 1(3):262-264. doi: 10.3969/j.issn.2096-8493.2020.03.011. doi: 10.3969/j.issn.2096-8493.2020.03.011
[5]	赵雁林, 逄宇. 结核病实验室检验规程. 北京: 人民卫生出版社, 2015.
[6]	中国防痨协会. 耐药结核病化学治疗指南(2019年简版). 中国防痨杂志, 2019, 41(10):1025-1073. doi: 10.3969/j.issn.1000-6621.2019.10.001. doi: 10.3969/j.issn.1000-6621.2019.10.001
[7]	全国第五次结核病流行病学抽样调查技术指导组, 全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告. 中国防痨杂志, 2012, 34(8):485-508.
[8]	Kumar P, Kumar P, Balooni V, et al. Genetic mutations associated with rifampicin and isoniazid resistance in MDR-TB patients in North-West India. Int J Tuberc Lung Dis, 2015, 19(4):434-439. doi: 10.5588/ijtld.14.0596. doi: 10.5588/ijtld.14.0596 pmid: 25859999
[9]	李永文, 李新旭, 耿红, 等. 山东省结核分枝杆菌的耐药流行状况. 中华结核和呼吸杂志, 2013, 36(9):667-670. doi: 10.3760/cma.j.issn.1001-0939.2013.09.007. doi: 10.3760/cma.j.issn.1001-0939.2013.09.007
[10]	王忠东, 张华强, 薛白, 等. 青岛地区耐药结核病流行现状及危险因素分析. 中国公共卫生, 2015, 31(9):1222-1224. doi: 10.11847/zgggws2015-31-09-35. doi: 10.11847/zgggws2015-31-09-35
[11]	Tao NN, He XC, Zhang XX, et al. Trends and characteristics of drug-resistant tuberculosis in rural Shandong, China. Int J Infect Dis, 2017, 65:8-14. doi: 10.1016/j.ijid.2017.09.019. doi: 10.1016/j.ijid.2017.09.019 URL
[12]	范大鹏, 岳永宁, 张艳, 等. 2014—2018年杭州市肺结核患者的耐药情况及其影响因素分析. 中国防痨杂志, 2021, 43(1):72-79. doi: 10.3969/j.issn.1000-6621.2021.01.014. doi: 10.3969/j.issn.1000-6621.2021.01.014
[13]	蔡春葵, 吕欣桐, 李刚, 等. 2012—2018年大连市肺结核患者耐药状况分析. 结核病与肺部健康杂志, 2019, 8(4):265-271. doi: 10.3969/j.issn.2095-3755.2019.04.007. doi: 10.3969/j.issn.2095-3755.2019.04.007
[14]	白桦, 郭婧玮, 胡培磊, 等. 2014—2018年湖南省耐药监测点结核分枝杆菌耐药监测结果分析. 中国防痨杂志, 2021, 43(4):365-369. doi: 10.3969/j.issn.1000-6621.2021.04.012. doi: 10.3969/j.issn.1000-6621.2021.04.012
[15]	Ahmed S, Shukla I, Fatima N, et al. Profile of drug-resistant-conferring mutations among new and previously treated pulmonary tuberculosis cases from Aligarh region of Northern India. Int J Mycobacteriol, 2018, 7(4):315-327. doi: 10.4103/ijmy.ijmy_98_18. doi: 10.4103/ijmy.ijmy_98_18 URL
[16]	程曦, 李亚斐, 饶英, 等. 2271例结核病患者耐药情况的流行病学特征分析. 重庆医学, 2015, 44(12):1635-1637. doi: 10.3969/j.issn.1671-8348.2015.12.016. doi: 10.3969/j.issn.1671-8348.2015.12.016
[17]	Wu B, Yu Y, Du C, et al. Epidemiology of drug-resistant tuberculosis in Chongqing, China: A retrospective observational study from 2010 to 2017. PLoS One, 2019, 14(12):e0216018. doi: 10.1371/journal.pone.0216018. doi: 10.1371/journal.pone.0216018 URL
[18]	Tripathy S, Kumar R, Singh SD. Prevalence of Multidrug Resistant Pulmonary Tuberculosis in North Bihar. J Clin Diagn Res, 2015, 9(11): LC09-12. doi: 10.7860/JCDR/2015/14024.6793. doi: 10.7860/JCDR/2015/14024.6793
[19]	Chan-Yeung M, Kam KM, Leung CC, et al. Population-based prospective molecular and conventional epidemiological study of tuberculosis in Hong Kong. Respirology, 2006, 11(4):442-448. doi: 10.1111/j.1440-1843.2006.00871.x. doi: 10.1111/j.1440-1843.2006.00871.x pmid: 16771914
[20]	杜巧丽, 杜昌廷, 杨健, 等. 2016—2018 年中国西部地区结核分枝杆菌耐药率及影响因素分析. 疾病监测, 2021, 36(5):495-500. doi: 10.3784/jbjc.202010290446. doi: 10.3784/jbjc.202010290446
[21]	Lin M, Zhong Y, Chen Z, et al. High incidence of drug-resis-tant Mycobacterium tuberculosis in Hainan Island, China. Trop Med Int Health, 2019, 24(9):1098-1103. doi: 10.1111/tmi.13285. doi: 10.1111/tmi.13285 URL
[22]	Huai P, Huang X, Cheng J, et al. Proportions and Risk Factors of Developing Multidrug Resistance Among Patients with Tuberculosis in China: A Population-Based Case-Control Study. Microb Drug Resist, 2016, 22(8):717-726. doi: 10.1089/mdr.2015.0186. doi: 10.1089/mdr.2015.0186 URL
[23]	闫莉, 关福源, 钟明浩, 等. 2018年结核病耐药情况及影响因素分析. 中国实验诊断学, 2020, 24(4):539-542. doi: 10.3969/j.issn.1007-4287.2020.04.001. doi: 10.3969/j.issn.1007-4287.2020.04.001

年份	培养阳性例数	总耐药[例 (耐药率,%)]	单耐药[例 (耐药率,%)]	耐多药[例 (耐药率,%)]	准广泛耐药[例 (耐药率,%)]	其他耐药[例 (耐药率,%)]
2016	92	46(50.00)	13(14.13)	28(30.43)	5(5.43)	0(0.00)
2017	64	32(50.00)	10(15.62)	16(25.00)	6(9.38)	0(0.00)
2018	135	33(24.44)	12(8.89)	11(8.15)	2(1.48)	8(5.93)
2019	359	58(16.16)	33(9.19)	11(3.06)	3(0.84)	11(3.06)
2020	454	105(23.13)	44(9.69)	19(4.19)	1(0.22)	41(9.03)
合计	1104	274(24.82)	112(10.14)	85(7.70)	17(1.54)	60(5.43)

人口学特征	例数(1104例)	耐药例数(274例)	耐药率(%)	χ²值	P值
性别				0.120	0.729
男性	805	202	25.09
女性	299	72	24.08
年龄组(岁)				10.177	0.017
14~20	48	3	6.25
21~40	359	98	27.30
41~60	290	70	24.14
61~95	407	103	25.31
职业				10.714	0.057
农民和民工	582	138	23.71
工人	119	29	24.37
行政事业单位人员	102	32	31.37
离退休人员	77	21	27.27
学生	72	9	12.50
其他	152	45	29.61
居住地				21.625	0.001
主城区	400	113	28.25
长清区	107	29	27.10
章丘区	158	51	32.28
莱芜区	199	31	15.58
济阳区	81	18	22.22
钢城区	51	6	11.76
郊区两县	108	26	24.07
患者分类				40.843	<0.001
初治患者	950	204	21.47
复治患者	154	70	45.45

变量	赋值	变量	赋值
因变量		居住地	主城区=1;长清区=2;章丘区=3;莱芜区=4;济阳区=5;钢城区=6;郊区两县=7
耐药	是=1 否=2
自变量
自变量		患者分类	初治患者=1;复治患者=2
年龄组	0~20岁=1;21~40岁=2;41~60岁=3;61~95岁=4	患者分类	初治患者=1;复治患者=2

变量	β值	$\bar{x}±s$值	Wald χ²值	P值	OR值	95%CI值
变量	β值	$\bar{x}±s$值	Wald χ²值	P值	OR值	上限	下限
年龄组(岁)
14~20					1.000
21~40	1.480	0.612	5.857	0.016	4.394	1.325	14.570
41~60	0.011	0.173	0.008	0.959	0.985	0.669	1.527
61~95	0.199	0.186	1.080	0.316	1.213	0.827	1.800
地区分布
主城区					1.000
长清区	-0.349	0.264	1.742	0.187	0.706	0.420	1.184
章丘区	-0.221	0.326	0.460	0.498	0.802	0.424	1.518
莱芜区	-0.433	0.293	2.180	0.140	0.648	0.365	1.152
济阳区	0.529	0.308	2.948	0.086	1.697	0.928	3.103
钢城区	0.177	0.363	0.239	0.625	1.194	0.586	2.432
郊区两县	0.863	0.501	2.969	0.085	2.371	0.888	6.329
患者分类
初治患者					1.000
复治患者	1.187	0.189	39.615	<0.001	3.276	2.264	4.740